Variance Stabilizing Transformation data generated by DESeq2 was used for principal component analyses to explore the primary variation in the data
Zepbound was approved by the Food and Drug Administration in November 2023 for weight loss in adults with obesity or who are overweight with at least one related condition like type 2 diabetes, high cholesterol, or high blood pressure)
In a Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023), participants using retatrutide experienced up to 24% reduction in body weight over 48 weeks, significantly outperforming earlier GLP-1 agents
Frequently Asked Questions Which medication produces more weight loss, Mazdutide or Retatrutide
In addition, the Western blot analysis further showed that the HFD-induced suppression of IR, IRS-1, p-AMPK, and p-ACC expression in the liver was also altered by NaB (Fig